558 related articles for article (PubMed ID: 33740349)
21. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
22. Sigma-1 Receptor Antagonists: A New Class of Neuromodulatory Analgesics.
Sánchez-Fernández C; Entrena JM; Baeyens JM; Cobos EJ
Adv Exp Med Biol; 2017; 964():109-132. PubMed ID: 28315268
[TBL] [Abstract][Full Text] [Related]
23. Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia.
Maione S; Starowicz K; Cristino L; Guida F; Palazzo E; Luongo L; Rossi F; Marabese I; de Novellis V; Di Marzo V
J Neurophysiol; 2009 May; 101(5):2411-22. PubMed ID: 19297510
[TBL] [Abstract][Full Text] [Related]
24. A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Malek N; Mrugala M; Makuch W; Kolosowska N; Przewlocka B; Binkowski M; Czaja M; Morera E; Di Marzo V; Starowicz K
Pain; 2015 May; 156(5):890-903. PubMed ID: 25719612
[TBL] [Abstract][Full Text] [Related]
25. Mother root of Aconitum carmichaelii Debeaux exerts antinociceptive effect in Complet Freund's Adjuvant-induced mice: roles of dynorpin/kappa-opioid system and transient receptor potential vanilloid type-1 ion channel.
Wang C; Sun D; Liu C; Zhu C; Jing X; Chen S; Liu C; Zhi K; Xu T; Wang H; Liu J; Xu Y; Liu Z; Lin N
J Transl Med; 2015 Aug; 13():284. PubMed ID: 26320055
[TBL] [Abstract][Full Text] [Related]
26. A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors.
Trevisan G; Rossato MF; Walker CI; Oliveira SM; Rosa F; Tonello R; Silva CR; Machado P; Boligon AA; Martins MA; Zanatta N; Bonacorso HG; Athayde ML; Rubin MA; Calixto JB; Ferreira J
Neuropharmacology; 2013 Oct; 73():261-73. PubMed ID: 23791558
[TBL] [Abstract][Full Text] [Related]
27. Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition.
Hua S; Cabot PJ
Pain Physician; 2013; 16(3):E199-216. PubMed ID: 23703419
[TBL] [Abstract][Full Text] [Related]
28. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
Mol Pain; 2016; 12():. PubMed ID: 27178246
[TBL] [Abstract][Full Text] [Related]
29. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
Costa B; Comelli F; Bettoni I; Colleoni M; Giagnoni G
Pain; 2008 Oct; 139(3):541-550. PubMed ID: 18602217
[TBL] [Abstract][Full Text] [Related]
30. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
31. Stronger antinociceptive efficacy of opioids at the injured nerve trunk than at its peripheral terminals in neuropathic pain.
Labuz D; Machelska H
J Pharmacol Exp Ther; 2013 Sep; 346(3):535-44. PubMed ID: 23820126
[TBL] [Abstract][Full Text] [Related]
32. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
33. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia.
Colvin LA; Bull F; Hales TG
Lancet; 2019 Apr; 393(10180):1558-1568. PubMed ID: 30983591
[TBL] [Abstract][Full Text] [Related]
34. Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain.
Leung A; Wallace MS; Ridgeway B; Yaksh T
Pain; 2001 Mar; 91(1-2):177-87. PubMed ID: 11240090
[TBL] [Abstract][Full Text] [Related]
35. Resistance to morphine analgesic tolerance in rats with deleted transient receptor potential vanilloid type 1-expressing sensory neurons.
Chen SR; Prunean A; Pan HM; Welker KL; Pan HL
Neuroscience; 2007 Mar; 145(2):676-85. PubMed ID: 17239544
[TBL] [Abstract][Full Text] [Related]
36. [Development of opioid tolerance -- molecular mechanisms and clinical consequences].
Freye E; Latasch L
Anasthesiol Intensivmed Notfallmed Schmerzther; 2003 Jan; 38(1):14-26. PubMed ID: 12522725
[TBL] [Abstract][Full Text] [Related]
37. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
38. Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain.
Haleem DJ
Pharmacol Res; 2018 Aug; 134():212-219. PubMed ID: 29969666
[TBL] [Abstract][Full Text] [Related]
39. Antiallodynic effect of intrathecal resiniferatoxin on neuropathic pain model of chronic constriction injury.
Parisi JR; Martins de Andrade AL; Torres Silva JR; Silva ML
Acta Neurobiol Exp (Wars); 2017; 77(4):317-322. PubMed ID: 29369297
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic potential of opioid/cannabinoid combinations in humans: Review of the evidence.
Babalonis S; Walsh SL
Eur Neuropsychopharmacol; 2020 Jul; 36():206-216. PubMed ID: 32273144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
